OBJECTIVE: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular disease (CVD) and mortality. We measured anti-cyclic citrullinated peptide (anti-CCP) antibody levels and determined use of disease-modifying antirheumatic drugs (DMARDs) among women in the Women's Health Initiative (WHI). Using these data, we undertook this study to assess total mortality over 10 years of followup among white, black, or Hispanic women with self-reported RA in the WHI. METHODS: Using stored baseline serum, we measured anti-CCP, rheumatoid factor (RF), and antinuclear antibodies (ANAs) in 9,988 women who reported having RA. Based on a previous chart review study, probable RA was defined as either self-reported RA and anti-CCP positivity, or anti-CCP negativity and DMARD use. Cox proportional hazards regression was used to model the relationship of self-reported RA, DMARD exposure, and anti-CCP positivity to total mortality, using followup data through April 2009. RESULTS: At baseline, the mean age was 62.8 years; 24.5% of subjects were black and 10% were Hispanic. Prevalence of anti-CCP positivity was 8.1% (n = 812), and 217 women were anti-CCP negative but had reported use of DMARDs; therefore, 1,029 women (of 9,988) were classified as having probable RA, and 8,958 were classified as unlikely to have RA (with data on DMARD use missing for 1 subject). Age-adjusted mortality rates were ∼2-fold higher for anti-CCP-positive women, with 20.2 deaths per 1,000 person-years, as compared to 11.4 deaths per 1,000 person-years among anti-CCP-negative women with self-reported RA who never used DMARDs. Among women who did not report any arthritis at baseline, we found 8.3 deaths per 1,000 person-years. The increased risk among anti-CCP-positive women with RA was not explained by age, RF positivity, ANA positivity, or DMARD use. CONCLUSION: Anti-CCP-positive RA was associated with substantial excess mortality among postmenopausal women in the WHI. This result was not explained by the risk factors we measured.
OBJECTIVE:Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular disease (CVD) and mortality. We measured anti-cyclic citrullinated peptide (anti-CCP) antibody levels and determined use of disease-modifying antirheumatic drugs (DMARDs) among women in the Women's Health Initiative (WHI). Using these data, we undertook this study to assess total mortality over 10 years of followup among white, black, or Hispanic women with self-reported RA in the WHI. METHODS: Using stored baseline serum, we measured anti-CCP, rheumatoid factor (RF), and antinuclear antibodies (ANAs) in 9,988 women who reported having RA. Based on a previous chart review study, probable RA was defined as either self-reported RA and anti-CCP positivity, or anti-CCP negativity and DMARD use. Cox proportional hazards regression was used to model the relationship of self-reported RA, DMARD exposure, and anti-CCP positivity to total mortality, using followup data through April 2009. RESULTS: At baseline, the mean age was 62.8 years; 24.5% of subjects were black and 10% were Hispanic. Prevalence of anti-CCP positivity was 8.1% (n = 812), and 217 women were anti-CCP negative but had reported use of DMARDs; therefore, 1,029 women (of 9,988) were classified as having probable RA, and 8,958 were classified as unlikely to have RA (with data on DMARD use missing for 1 subject). Age-adjusted mortality rates were ∼2-fold higher for anti-CCP-positive women, with 20.2 deaths per 1,000 person-years, as compared to 11.4 deaths per 1,000 person-years among anti-CCP-negative women with self-reported RA who never used DMARDs. Among women who did not report any arthritis at baseline, we found 8.3 deaths per 1,000 person-years. The increased risk among anti-CCP-positive women with RA was not explained by age, RF positivity, ANA positivity, or DMARD use. CONCLUSION: Anti-CCP-positive RA was associated with substantial excess mortality among postmenopausal women in the WHI. This result was not explained by the risk factors we measured.
Authors: Thomas J Richards; Naftali Kaminski; Fred Baribaud; Susan Flavin; Carrie Brodmerkel; Daniel Horowitz; Katherine Li; Jiin Choi; Louis J Vuga; Kathleen O Lindell; Melinda Klesen; Yingze Zhang; Kevin F Gibson Journal: Am J Respir Crit Care Med Date: 2012-01-01 Impact factor: 21.405
Authors: Minoru Satoh; Edward K L Chan; Lindsey A Ho; Kathryn M Rose; Christine G Parks; Richard D Cohn; Todd A Jusko; Nigel J Walker; Dori R Germolec; Irene Z Whitt; Patrick W Crockett; Brad A Pauley; Jason Y F Chan; Steven J Ross; Linda S Birnbaum; Darryl C Zeldin; Frederick W Miller Journal: Arthritis Rheum Date: 2012-07
Authors: Jeffrey D Greenberg; Joel M Kremer; Jeffrey R Curtis; Marc C Hochberg; George Reed; Peter Tsao; Michael E Farkouh; Adeel Nasir; Soko Setoguchi; Daniel H Solomon Journal: Ann Rheum Dis Date: 2010-11-24 Impact factor: 19.103
Authors: E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel Journal: Arthritis Rheum Date: 2000-08
Authors: Paulo J Nicola; Hilal Maradit-Kremers; Véronique L Roger; Steven J Jacobsen; Cynthia S Crowson; Karla V Ballman; Sherine E Gabriel Journal: Arthritis Rheum Date: 2005-02
Authors: Angel Gonzalez; Hilal Maradit Kremers; Cynthia S Crowson; Paulo J Nicola; John M Davis; Terry M Therneau; Veronique L Roger; Sherine E Gabriel Journal: Arthritis Rheum Date: 2007-11
Authors: Jeffrey A Sparks; Shun-Chiao Chang; Katherine P Liao; Bing Lu; Alexander R Fine; Daniel H Solomon; Karen H Costenbader; Elizabeth W Karlson Journal: Arthritis Care Res (Hoboken) Date: 2016-06 Impact factor: 4.794
Authors: Jeffrey A Sparks; Shun-Chiao Chang; Uyen-Sa D T Nguyen; Medha Barbhaiya; Sara K Tedeschi; Bing Lu; Karen H Costenbader; Yuqing Zhang; Hyon K Choi; Elizabeth W Karlson Journal: Arthritis Care Res (Hoboken) Date: 2017-12-15 Impact factor: 4.794
Authors: Rachel H Mackey; Lewis H Kuller; Kevin D Deane; Brian T Walitt; Yue-Fang Chang; V Michael Holers; William H Robinson; Russell P Tracy; Mark A Hlatky; Charles B Eaton; Simin Liu; Matthew S Freiberg; Mehret Birru Talabi; Erik B Schelbert; Larry W Moreland Journal: Arthritis Rheumatol Date: 2015-09 Impact factor: 10.995
Authors: Mehret Birru Talabi; Rachel H Mackey; Lewis H Kuller; Janice S Dorman; Kevin D Deane; William H Robinson; Brian T Walitt; Yuefang Chang; V Michael Holers; Simin Liu; Larry W Moreland Journal: Am J Epidemiol Date: 2017-07-15 Impact factor: 4.897
Authors: Helen C S Meier; Dale P Sandler; Eleanor M Simonsick; Nan-Ping Weng; Christine G Parks Journal: Exp Gerontol Date: 2020-03-05 Impact factor: 4.032
Authors: Isabela M Bensenor; Alessandra C Goulart; Alexandre C Pereira; André R Brunoni; Airlane Alencar; Raul D Santos; Márcio S Bittencourt; Rosa W Telles; Luciana Andrade Carneiro Machado; Sandhi Maria Barreto; Bianca de Almeida-Pititto; Carolina Porto Silva Janovsky; José Augusto Sgarbi; William R Tebar; Vandrize Meneghini; Fernando Barbosa Junior; Ana Cristina de Medeiros Ribeiro; Sandra Gofinet Pasoto; Rosa Maria R Pereira; Eloísa Bonfá; Aytan M Sipahi; Itamar de S Santos; Paulo A Lotufo Journal: Clinics (Sao Paulo) Date: 2022-04-06 Impact factor: 2.365
Authors: Christine G Parks; Aline de Souza Espindola Santos; Catherine C Lerro; Curt T DellaValle; Mary H Ward; Michael C Alavanja; Sonja I Berndt; Laura E Beane Freeman; Dale P Sandler; Jonathan N Hofmann Journal: Front Immunol Date: 2019-07-11 Impact factor: 7.561
Authors: Laura Vidal-Bralo; Eva Perez-Pampin; Cristina Regueiro; Ariana Montes; Rosana Varela; Maria Dolores Boveda; Juan J Gomez-Reino; Antonio Gonzalez Journal: PLoS One Date: 2017-07-03 Impact factor: 3.240